{"id":"NCT01254643","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).","officialTitle":"A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-12","primaryCompletion":"2013-08-10","completion":"2013-08-10","firstPosted":"2010-12-06","resultsPosted":"2014-12-22","lastUpdate":"2018-11-28"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V503","otherNames":[]}],"arms":[{"label":"All Enrolled","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV) strains contained in the vaccine. The success criterion for the primary analysis requires that point estimates for seroconversion rate be greater than 90% for all 9 HPV types.","primaryOutcome":{"measure":"Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine","timeFrame":"4 weeks post-vaccination 3 (Month 7)","effectByArm":[{"arm":"All Enrolled","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28003597"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Injection site pain","Injection site swelling","Injection site erythema","Nasopharyngitis","Headache"]}}